Related Experiment Video
Updated: Feb 15, 2026

Orthotopic Mouse Model of Colorectal Cancer
Published on: December 4, 2007
Epigenetic inactivation of RUNX3 in colorectal cancer
Eung Jin Shin1, Han Jo Kim2, Myoung Won Son1
1Department of Surgery, Soonchunhyang University College of Medicine, Cheonan, Korea.
Purpose:
Emerging evidence indicates that runt-related transcription factor 3 (RUNX3) is an important tumor suppressor gene in several cancer types, including colorectal cancer (CRC). However, the clinical significance of RUNX3 inactivation in CRC remains unclear. The aim of this study was to examine the correlation between clinicopathologic factors and RUNX3 hypermethylation/expression in CRC.
Methods:
Sixty-two CRC patients who were treated at the Soonchunhyang University College of Medicine were recruited in this study. The hypermethylation of CpG islands in the RUNX3 promoter and the expression of RUNX3 mRNA were identified by methylation-specific polymerase chain reaction (PCR) and reverse transcriptase-PCR, respectively. The expression of RUNX3 was determined by immunohistochemical staining.
Results:
Of the 62 CRC tissue samples, 20 (32.3%) presented hypermethylated RUNX3 promoters. Aberrant RUNX3 hypermethylation was found to be associated with vascular (P = 0.006) and lymphatic (P = 0.002) invasion. Hypermethylation of RUNX3 was associated with poor survival outcomes (P = 0.038). However, expression of RUNX3 was not a prognostic factor (P = 0.363).
Conclusion:
Hypermethylation of RUNX3 may be a predictor of a poor prognosis in CRC.
Insights
RUNX3 hypermethylation is linked to poor prognosis in colorectal cancer (CRC). This epigenetic change, not RUNX3 expression, may predict outcomes in CRC patients, highlighting its clinical significance.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Runt-related transcription factor 3 (RUNX3) acts as a tumor suppressor gene in various cancers.
- The clinical impact of RUNX3 inactivation in colorectal cancer (CRC) requires further elucidation.
Purpose of the Study:
- To investigate the association between clinicopathological factors and RUNX3 promoter hypermethylation and RUNX3 gene expression in CRC patients.
Main Methods:
- Analyzed 62 CRC tissue samples using methylation-specific PCR for RUNX3 promoter hypermethylation.
- Assessed RUNX3 mRNA expression via reverse transcriptase-PCR and protein levels through immunohistochemical staining.
Main Results:
- RUNX3 promoter hypermethylation was observed in 32.3% of CRC samples.
- Hypermethylation correlated significantly with vascular invasion (P=0.006) and lymphatic invasion (P=0.002).
- RUNX3 hypermethylation was associated with poorer survival outcomes (P=0.038), while RUNX3 expression was not a prognostic factor (P=0.363).
Conclusions:
- RUNX3 promoter hypermethylation may serve as a predictive biomarker for poor prognosis in colorectal cancer.
Related Concept Videos
X-Inactivation
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Activation and Inactivation of G Proteins
Cancer
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...

